#USA #Miami #Navigantis #VASCO #Robotic Platform

Navigantis Inc. Advances Neurovascular Care with VASCO Robotic Platform

Navigantis Inc., a pioneering entity in interventional robotics, has achieved a monumental milestone by successfully conducting its first neurovascular clinical cases using the VASCO interventional robotic platform. This significant step in medical technology was recently announced and reflects the company's ongoing commitment to leveraging robotics in healthcare.

Transforming Neurovascular Procedures

The use of the VASCO platform targets patients suffering from various neurovascular disorders, such as those needing diagnostic cerebral angiograms, brain tumor embolizations, and mechanical thrombectomy for ischemic stroke recovery. Mor Dayan, CEO of Navigantis Inc., expressed the significance of this achievement, stating, “This success is vital in our mission to integrate robotic procedures in the neurovascular field. Implementing robotics can enhance both patient outcomes and procedural efficiency.”

This groundbreaking approach aims not only to streamline existing processes but also to capitalize on advancements leading to robotic telesurgery for stroke patients. This innovation could revolutionize critical care, drastically reducing response times and broadening access to timely treatments necessary for optimal patient recovery.

Expert Leadership and Innovative Trials

The neurovascular interventional robotic clinical trial is under the guidance of Professor Dong Joon Kim, a leading figure in robotic neurointervention and the Chairman of Radiology at Severance Hospital in Seoul, South Korea. He stated, “These first successful robotic cases are a major stepping stone towards treating more complex neurovascular diseases.” Professor Kim's involvement emphasizes the expertise and leadership that underpins this trial.

This recent development builds upon Navigantis’ earlier successes, notably the First-In-Human (FIH) trials conducted in 2022, which saw the earlier version of the VASCO platform successfully perform robotic embolization of liver tumors. The continuity of innovation marks Navigantis' dedication and capable execution within the realm of health technology.

Upcoming Events and Future Directions

The anticipation surrounding Navigantis does not end here; CEO Mor Dayan is expected to represent the company at the 43rd J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. This event could potentially open doors for further partnerships and insights into advancing robotic platforms in neurovascular care.

About Navigantis Inc.

Navigantis Inc. is at the forefront of developing interventional robotic solutions for an array of neurovascular procedures, extending its capabilities to areas such as acute ischemic stroke. The VASCO robotic platform is currently classified as an investigational device and is undergoing evaluation outside the United States. Notably, it has not yet received approval for commercial use across jurisdictions, including the U.S.

For additional details about Navigantis and its innovative technologies, visit Navigantis Website or connect on LinkedIn. As advancements in robotics continue to shape the healthcare landscape, Navigantis Inc. stands poised for an impactful future in medical treatments.